Wells Fargo Initiates Coverage On DICE Therapeutics with Equal-Weight Rating, Announces Price Target of $38
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Derek Archila initiates coverage on DICE Therapeutics (NASDAQ:DICE) with an Equal-Weight rating and a price target of $38.
May 24, 2023 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Wells Fargo initiates coverage on DICE Therapeutics with an Equal-Weight rating and a price target of $38.
The initiation of coverage by Wells Fargo with an Equal-Weight rating suggests that the analyst believes DICE Therapeutics is fairly valued at its current price. The price target of $38 indicates the analyst's expectation for the stock's future performance. This news is relevant and important for investors in DICE, but the neutral rating suggests a short-term price impact of 0.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100